Novo Nordisk hit hard as U.S. rebuffs insulin drug

[Anonymous]

Dry pipeline for several years now..this is terrible,news. Stuck with Levemir (the dog of basals) and Victoza, which will soon lose share to Bydureon-plus other GLP's will be out soon and the SLG2's. we are stuck with nothing valid to talk about except Duration 6 a .2 A1c difference while trying to conceal the poor tolerability of Victoza.

Novo management wants us to believe it's just about the FDA being out to get us. Perhaps the agency has a point in saying that the benefit of the Degludec suite is so low that the accompanying risk has to be essentially zero ?

 

[Anonymous]

Dry pipeline for several years now..this is terrible,news. Stuck with Levemir (the dog of basals) and Victoza, which will soon lose share to Bydureon-plus other GLP's will be out soon and the SLG2's. we are stuck with nothing valid to talk about except Duration 6 a .2 A1c difference while trying to conceal the poor tolerability of Victoza.

All true, but at least now we have PODS to help us sell these drugs. Ooops, I have to go. On Point call is in 15 minutes.

 

[Anonymous]

All true, but at least now we have PODS to help us sell these drugs. Ooops, I have to go. On Point call is in 15 minutes.

"On Point" calls are about to turn into "On the Block" calls.

 

[Anonymous]

So glad and thankful I didn't get hired by this train-wreck of a company!

 

[Anonymous]

Bend over and kiss your collective asses goodbye. Another Pharma fuck-up hiring on speculation.

 

[Anonymous]

So glad and thankful I didn't get hired by this train-wreck of a company!

ditto -- this couldn't have happened to a nicer bunch of arse holes

 

[Anonymous]

So glad and thankful I didn't get hired by this train-wreck of a company!

Hey, if your company strung together 40+ consecutive quarters of double digit growth like we have, you wouldnt be looking for a job HERE, now would you?

 

[Anonymous]

Hey, if your company strung together 40+ consecutive quarters of double digit growth like we have, you wouldnt be looking for a job HERE, now would you?

You will be among the first we let go. Dumb people are always first. For once in your life, you will be first. Congratulations dumb person.

 

[Anonymous]

Were are all the power statements from the new hires. Sheeple.

Boy things go from golden goose to rust chicken quickly. Enjoy the ride. It's going to be long and bumpy. Tools.

 

[Anonymous]

This is too funny - all you smug new hires during the expansion with your look at me look at how special I am with my fake Top 20% performance and all those a-hole new hire managers who couldnt pickl talent from a barrel - can not wait to see you uesless asses on the unemployment line - love when egomaniacs get a dose of reality

 

[Anonymous]

This is too funny - all you smug new hires during the expansion with your look at me look at how special I am with my fake Top 20% performance and all those a-hole new hire managers who couldnt pickl talent from a barrel - can not wait to see you uesless asses on the unemployment line - love when egomaniacs get a dose of reality

Sorry you didn't pass the test.

 

[Anonymous]

Ouch! feel for you guys over the pond, the FDA does seem to enjoy going a different way to the other authorities around the world, I would hate to be in a US regulatory job where you are trying to predict what they are going to do next. My shares didn't half take a hit too.

Just got my first script on my territory (7 days after launch) and so far it is tracking well ahead of target in the UK. LOTS of complaining about the price though (40% more than Lantus/Levemir).

Japan's launch is imminent too and that is a VERY conservative market,

 

[Anonymous]

So far most degludec patients in the UK seem to be patients where the doctors have had several hospital admissions (DKA or hypos) and compliance with insulin is regarded as a big part of the problem.
The hypo angle is important but not as important as the fact that degludec is still effective when patients are erratic with their dosing and simply can't/won't inject at the same time every day.
So older patients, shift workers, 18-25 yo type 1s, people in care homes who need a nurse to come and do their injections etc etc etc.
Remember it is a socialized system so PCPs are willing to invest in a drug with large price premium if it is going to save $1,000s in hospital admission fees from their budget.

 

[Anonymous]

So far most degludec patients in the UK seem to be patients where the doctors have had several hospital admissions (DKA or hypos) and compliance with insulin is regarded as a big part of the problem.
The hypo angle is important but not as important as the fact that degludec is still effective when patients are erratic with their dosing and simply can't/won't inject at the same time every day.
So older patients, shift workers, 18-25 yo type 1s, people in care homes who need a nurse to come and do their injections etc etc etc.
Remember it is a socialized system so PCPs are willing to invest in a drug with large price premium if it is going to save $1,000s in hospital admission fees from their budget.

Corp shill policing cafepharma

 

[Anonymous]

So far most degludec patients in the UK seem to be patients where the doctors have had several hospital admissions (DKA or hypos) and compliance with insulin is regarded as a big part of the problem.
The hypo angle is important but not as important as the fact that degludec is still effective when patients are erratic with their dosing and simply can't/won't inject at the same time every day.
So older patients, shift workers, 18-25 yo type 1s, people in care homes who need a nurse to come and do their injections etc etc etc.
Remember it is a socialized system so PCPs are willing to invest in a drug with large price premium if it is going to save $1,000s in hospital admission fees from their budget.

BS! I think you are a company plant trying to rally the troops.

 

[Anonymous]

BS! I think you are a company plant trying to rally the troops.

Poster #35 here. My point is that the drug was launched in the UK just a little time ago, and we are supposed to believe that we've already gotten the type of post-launch data that the supposed UK poster put forth as fact (the majority of the degludec use is in hospitals, physicians in a socialized medical system write it because they know degludec use will save many thousands of dollars)?
I HATE it when they think that we're stupid. Stop with the lies and excuses ("the FDA is out to get us!!"), do the CVOT already, and stop feeding us BS to keep us in the dark!

Thank you.

 

[Anonymous]

lmao @ this shitbag company

 

[Anonymous]

By the time this gets approved, Lilly will have generic Lantus out in the market and from the premium price we will have we would be lucky to get one script!!! Especially with the Affordable Care Act in 2014! Note I said AFFORDABLE! We're toast!

 

[Anonymous]

patients are erratic with their dosing and simply can't/won't inject every day..

Great point. It is very hard for patients to inject something every single day. When good control is measured by Hba1c and patients miss several injections a month, it makes sense that a glucose control agent with less rigorous dosing schedule would be beneficial to many people suffering with T2D.
Something like a weekly injection maybe?

 

[Anonymous]

Miss a dose of a 1/wk dour and you're screwed!